Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0001518

Haloperidol für die Peakidentifizierung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Haloperidol, 4-[4-(4-Chlorphenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorphenyl)-1-butanon, 4-[4-(4-Chlorphenyl)-4-hydroxypiperidino]-4′-fluorbutyrophenon, 4-[4-(p-Chlorphenyl)-4-hydroxypiperidino]-4′-fluorbutyrophenon

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H23ClFNO2
CAS-Nummer:
52-86-8
Molekulargewicht:
375.86
MDL-Nummer:
MFCD00051423
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831469
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

haloperidol

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

InChIKey

LNEPOXFFQSENCJ-UHFFFAOYSA-N

Angaben zum Gen

human ... HTR2A(3356)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Haloperidol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

H0100000

Haloperidol, European Pharmacopoeia (EP) Reference Standard

1303002

Haloperidol, United States Pharmacopeia (USP) Reference Standard

H0100100

Haloperidoldecanoat, European Pharmacopoeia (EP) Reference Standard

Y0001517

Haloperidol für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

1303013

Haloperidol-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1303057

Haloperidoldecanoat, United States Pharmacopeia (USP) Reference Standard

1303024

Haloperidol-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

PHR1724

Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material

BP407

Haloperidol, British Pharmacopoeia (BP) Reference Standard

PHR8951

Haloperidol-verwandte Verbindung A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8714

Haloperidol-verwandte Verbindung B, certified reference material, pharmaceutical secondary standard

Piktogramme

Skull and crossbonesHealth hazard
GHS06,GHS08

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Mark C Fok et al.
International journal of geriatric psychiatry, 30(4), 333-344 (2015-02-03)
To summarize the effect of antipsychotics for preventing postoperative delirium. We conducted a literature search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and clinicaltrials.gov. We included randomized controlled trials of adults undergoing surgery
Paul Perkins et al.
The Cochrane database of systematic reviews, (2)(2), CD006271-CD006271 (2009-04-17)
Nausea and vomiting are common symptoms of patients with terminal, incurable illnesses and can be distressing. The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of
Marianne Klemp et al.
Journal of clinical psychopharmacology, 31(6), 698-704 (2011-10-25)
The objective of the study was to examine the efficacy and the degree of adverse effects connected with atypical neuroleptic drugs and haloperidol by using a previously described Bayesian statistical method that includes both direct and indirect comparisons simultaneously. The
Robin Nguyen et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(45), 14948-14960 (2014-11-08)
Hyperactivity within the ventral hippocampus (vHPC) has been linked to both psychosis in humans and behavioral deficits in animal models of schizophrenia. A local decrease in GABA-mediated inhibition, particularly involving parvalbumin (PV)-expressing GABA neurons, has been proposed as a key
Erica H Z Wang et al.
Neurocritical care, 16(1), 170-183 (2011-11-01)
Delirium is the most common mental disturbance in critically-ill patients and results in significant morbidity and mortality. Haloperidol is a preferred agent for the treatment of delirium in this population because of its rapid onset of action and lack of
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.